Delivery of soluble tumor necrosis factor receptor from in-situ forming PLGA implants: In-vivo

Pharmaceutical Research

Volumn 17, Issue 12, 2000, Pages 1546-1550

  Eliaz, R E ^a,b   Wallach, D ^c   Kost, J ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Biodegradable polymers; In situ; In vivo in vitro correlation; Injectable implant delivery system; Protein peptide delivery system; TNF soluble receptors

Indexed keywords

POLYGLACTIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; IN VIVO STUDY; INFLAMMATORY DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG IMPLANTS; INJECTIONS, SUBCUTANEOUS; LACTIC ACID; MICE; MICE, NUDE; POLYGLYCOLIC ACID; POLYMERS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I;

EID: 0034467890     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007621512647     Document Type: Article

References (26)

1. Isolation and characterization of a tumor necrosis binding protein from urine
2. Purification and biologic characterization of a specific tumor necrosis factor α inhibitor
3. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity
4. Two tumor necrosis factor-binding proteins purified from human urine
5. Elevated serum levels of soluble tumor necrosis factor receptors (sTNF-R) in patients with HIV infection
6. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases
7. Infusion of tumor necrosis factor causes an increase in circulating TNF-binding proteins in humans
8. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lups erythematosus
9. Tumor necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy
10. LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma
11. Elevated tumor necrosis-alpha (TNF-alpha) biological activity in psoriatic skin lesions
12. Interleukin-6, tumor necrosis factor and soluble tumor necrosis factor receptors in women with pre-eclampsia
13. Long-term protection against the effects of tumor necrosis factor by controlled delivery of the soluble p 55 TNF receptor
14. Sustained release of cisplatin in dogs from an injectable implant delivery system
15. A new injectable carbamazepine solution - Antiepileptic effects and pharmaceutical properties
16. The evaluation of glycofurol as a vehicle for use in toxicity studies
17. Pharmacokinetic and pharmacodynamic response after intranasal administration of diazepam to rabbits
18. Intravenous carbamazepine: Comparison of different parenteral formulations in a mouse model of convulsive status epilepticus
19. Intranasal administration of insulin to rabbits using glycofurol as an absorption promoter
20. Evaluation of local toxicity after repeated intranasal vaccination of guinea-pigs
21. Characterization of a polymeric PLGA injectable implant delivery system for the controlled release of proteins
22. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients
23. Tumors secreting human TNF/cachectin induce cachexia in mice
24. Cloning of genomic DNA for tumor necrosis factor and efficient expression in CHO cells
25. Controlled release of microquantities of macromolecules